Publication patterns in the BPC-157 literature, examined posts 31–46

BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.

Building on post #31 rather than restating it.

The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.

It is the sort of thing that seems obvious in retrospect and was not at the time.

Everything in post #31 holds. The case it does not cover is the one I have.

My experience of publication patterns contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.

Adding a data point of agreement rather than a data point.

Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

I read post #35 twice before replying, because I had assumed the opposite.

Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.

Post #35 answers the question as asked. The question underneath it is different.

The question underneath publication patterns is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.

Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.

Two people in this thread mean different things by publication patterns and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.

Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.

Take the reasoning and check the arithmetic; I do not always get it right.

Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.

That matches what I was told, which is not the same as knowing it.

On post #38 — agreed on the reasoning, with one qualification.

I have no financial interest in anything named in this thread and I want to say so before I comment on publication patterns, because it is the sort of subject where it matters.

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

Speaking for myself and not for anyone else who has posted here.

The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.

The variance between people here is larger than the effect being discussed.